Background: In patients who survive an acute myocardial infarction (AMI), angiotensin-
converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events …

Background Patients who sustain an acute myocardial infarction (AMI), including ST-
segment elevation myocardial infarction (STEMI) and non–ST-segment elevation myocardial …

Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …

Acute myocardial infarction (MI) is one of the leading global healthcare emergencies,
contributing to over three million global deaths. The purpose of this study is to investigate …

Aims Patients surviving an acute myocardial infarction (AMI) are at risk of developing
symptomatic heart failure (HF) or premature death. We hypothesized that …

Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction
have an increased risk of death and heart failure. Numerous clinical studies have …

Background Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart
failure with reduced ejection fraction (HF-REF) and after myocardial infarction (MI). We …

• The industry-sponsored, international, multicenter, randomized, double-blind, active-
comparator trial, PARADISE-MI 1 (Prospective ARNI vs. ACE Inhibitor Trial to Determine …

Aim The win ratio can incorporate different types of outcomes and enhance statistical power,
making it a useful method for analysing composite outcomes in cardiovascular trials. The …